• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4595230)   Today's Articles (9)   Subscriber (49331)
Number Citation Analysis
26
Si TG, Li L, Guo Z, Xu B. [Chinese expert consensus on perioperative management of renal tumor cryoablation (2022 edition)]. ZHONGHUA NEI KE ZA ZHI 2023;62:363-368. [PMID: 37032130 DOI: 10.3760/cma.j.cn112138-20221024-00780] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/11/2023]
27
Meng L, Wang W, Xu B, Qin J, Zhang K, Liu H. Solution-Processed Flexible Transparent Electrodes for Printable Electronics. ACS NANO 2023;17:4180-4192. [PMID: 36826227 DOI: 10.1021/acsnano.2c10999] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/18/2023]
28
Chen Y, Zhu P, Xu JJ, Song Y, Jiang L, Gao LJ, Chen J, Song L, Gao Z, Liu HB, Yang YJ, Gao RL, Xu B, Yuan JQ. [Clinical features and long-term prognosis of diabetic patients with low or intermediate complexity coronary artery disease post percutaneous coronary intervention]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2023;51:143-150. [PMID: 36789593 DOI: 10.3760/cma.j.cn112148-20220601-00432] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/16/2023]
29
Wu JY, Xu B, Zhu XJ, Ming X, Luo H, Mao X, Gu J, Zhou JF, Xiao Y. [PD-1 inhibitor in chronic active Epstein-Barr virus infection: a report of six cases and literature review]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2023;44:165-168. [PMID: 36948875 PMCID: PMC10033261 DOI: 10.3760/cma.j.issn.0253-2727.2023.02.016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Subscribe] [Scholar Register] [Indexed: 03/24/2023]
30
Xu B, Wu C, Jin WH, Zhang YP, Fang H, Chao ZM. Extraction and Crystal Structure of Fucosterol. CRYSTALLOGR REP+ 2022. [DOI: 10.1134/s106377452207015x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/12/2023]
31
Xu B, Ma F, Wang S, Tong Z, Li W, Wu X, Wang X, Sun T, Pan Y, Yao H, Wang X, Luo T, Yang J, Zeng X, Zhao W, Cong X, Wang N, Xu C, Chen J. 22MO Efficacy and safety of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer (mTNBC) by baseline HER2 expression level: Subgroup analysis from a phase IIb trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/05/2022]  Open
32
Shao Z, Liu Q, Tong Z, Li W, Cai L, Bai Y, Amin K, Deshpande P, Bi Y, Xu B. 21MO Primary results of a China bridging, phase II randomized study of initial endocrine therapy (ET) ± ribociclib (RIB) in pre- & postmenopausal Chinese women with HR+/HER2– ABC. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.10.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/07/2022]  Open
33
Zheng R, Zhang Y, Chen R, Pan C, Chen X, Xu B. Necessity of External Iliac Lymph Nodes and Inguinal Nodes Radiation in Rectal Cancer with Anal Canal Involvement. Int J Radiat Oncol Biol Phys 2022. [DOI: 10.1016/j.ijrobp.2022.07.1012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/31/2022]
34
Huang W, Leng JH, Pei TJ, Li R, Ruan XY, Xu B, Liang XY, Wang GY, Zhou YF, Xu CJ, Zhang XM, Yao SZ, Lu MS, Ma XX, Liu CD, Xue Q, Tang L, Dai Y, Liu Y, Deng S, Guan J, Zhang W, Li L, Ren CC, He YD, Yang XY, Ouyang YW, Zhu HL, Xiao L, Chen G, Lang JH. [Fertility protection and preservation for patients with endometriosis: a Chinese consensus (2022)]. ZHONGHUA FU CHAN KE ZA ZHI 2022;57:733-739. [PMID: 36299175 DOI: 10.3760/cma.j.cn112141-20220427-00329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
35
Hughes D, Wilson R, Saijo Y, Chan N, Kumar A, Grimm R, Griffin B, Tang W, Nissen S, Aminian A, Xu B. Impact of weight loss on cardiac function: improvement in left ventricular global longitudinal strain following metabolic surgery. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]  Open
36
Zhang HC, Zhang Y, Dai HB, Wu D, Xu B. Preoperative anemia and complications after total joint arthroplasty: a systematic review and meta-analysis. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2022;26:7420-7430. [PMID: 36314312 DOI: 10.26355/eurrev_202210_30011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
37
Ueno N, Jacot W, Yamashita T, Sohn J, Tokunaga E, Prat A, Tsurutani J, Park Y, Rugo H, Xu B, Cardoso F, Mitri Z, Mahtani R, Dunton K, Wang Y, Gambhire D, Cottone F, Harbeck N, Cameron D, Modi S. 217O Patient-reported outcomes (PROs) from DESTINY-Breast04, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs treatment of physician's choice (TPC) in patients (pts) with HER2-low metastatic breast cancer (MBC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.256] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
38
Xu B, Ma F, Wang S, Tong Z, Li W, Wu X, Wang X, Sun T, Pan Y, Yao H, Wang X, Luo T, Yang J, Zeng X, Zhao W, Cong X, Chen J. 248P Sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
39
Fan Y, Ji D, Luo Y, Wang J, Chen S, Lan B, Xu B. 207P Comparison of CDK4/6 inhibitors, PI3K/mTOR inhibitors, and HDAC inhibitors in the second-line treatment of hormone receptor-positive, HER2-negative advanced breast cancer: A network meta-analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
40
Zhang P, Zhang Q, Hu X, Li W, Tong Z, Sun T, Teng Y, Wu X, Ouyang Q, Yan X, Cheng J, Liu Q, Feng J, Wang X, Xu G, Wu F, Xia B, Xu B. 229P Dalpiciclib plus fulvestrant in HR+/HER2− advanced breast cancer (ABC): Updated analysis from the phase III DAWNA-1 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]  Open
41
Hu X, Broughton E, Li W, Sun T, Shen K, Huang C, Sriuranpong V, Ngan K, Chia Y, Bhattacharyya H, Zhao H, Shen J, Xu B. 218P Patient-reported quality of life in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) advanced breast cancer (ABC) treated with palbociclib (PAL) plus letrozole (LET): Results from PALOMA-4. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.257] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
42
Kaufman P, Twelves C, Awada A, Im SA, Vahdat L, Xu B, Yuan P, Hauck W, Xie R, Lalayan B, Cortés J. 259P Efficacy of eribulin mesylate in HER2-low metastatic breast cancer (MBC): Results from three phase III studies. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
43
Xu B, Zhang Q, Zhang P, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Teng Y, Pan Y, Yan X, Wang Y, Xie W, Zeng X, Jiang S, Bayaxi N, Zhu X. LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
44
Hile G, Ma F, Victory A, Xu B, Pedersen E, Wasikowski R, Berthier C, Nechiporchik N, Ognenovski V, Schiopu E, Billi A, Gudjonsson J, Kahlenberg J. 039 Single-cell RNA-sequencing captures the cellular diversity within lesional and non-lesional skin of patients with dermatomyositis. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.05.093] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
45
Lönnblom E, Leu Agelii M, Sareila O, Hafström I, Andersson M, Cheng L, Bergström G, Ekwall AKH, Rudin A, Kastbom A, Sjowall C, Xu B, Jacobsson LTH, Viljanen J, Kihlberg J, Gjertsson I, Holmdahl R. POS0562 AUTOANTIBODIES TO JOINT PROTEINS AS NOVEL BIOMARKERS FOR THE DIAGNOSIS OF UNTREATED EARLY RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.3698] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
46
Xu B, Chen X, Shi Z, Meng L, Wang D, Jiang L, Liu H. Electrochemical On-Site Switching of the Directional Liquid Transport on a Conical Fiber. ADVANCED MATERIALS (DEERFIELD BEACH, FLA.) 2022;34:e2200759. [PMID: 35419895 DOI: 10.1002/adma.202200759] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 04/02/2022] [Indexed: 06/14/2023]
47
Tang Z, Wang P, Xu B, Meng L, Jiang L, Liu H. Bioinspired Robust Water Repellency in High Humidity by Micro-meter-Scaled Conical Fibers: Toward a Long-Time Underwater Aerobic Reaction. J Am Chem Soc 2022;144:10950-10957. [PMID: 35617313 DOI: 10.1021/jacs.2c03860] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
48
Xu JJ, Zhu P, Song Y, Yuan DS, Jia SD, Zhao XY, Yao Y, Jiang L, Xu N, Li JX, Zhang Y, Song L, Gao LJ, Chen JL, Qiao SB, Yang YJ, Xu B, Gao RL, Yuan JQ. [Impact of prolonging dual antiplatelet therapy on long-term prognosis of elderly patients with coronary heart disease complicated with diabetes mellitus undergoing drug-eluting stent implantation]. ZHONGHUA XIN XUE GUAN BING ZA ZHI 2022;50:450-457. [PMID: 35589593 DOI: 10.3760/cma.j.cn112148-20211120-01002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
49
Zhang J, Wang J, Fan J, Xu B, Qiao Y. 201P Metastatic and survival characteristics of de novo versus relapsed breast cancer in females aged>35-years-old: A nationwide multicenter study based on hospital population. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.03.220] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]  Open
50
Cheng L, Li Y, Yao Y, Jin X, Ying H, Xu B, Xu J. Toxic Effects of Thioacetamide-Induced Femoral Damage in New Zealand White Rabbits by Activating the p38/ERK Signaling Pathway. Physiol Res 2022;71:285-295. [DOI: 10.33549/physiolres.934803] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]  Open
PrevPage 2 of 42 123454142Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA